PET Drugs Without An IND Get Three More Years For Studies Under FDA Guidance
This article was originally published in The Pink Sheet Daily
Q&A document from agency says sponsor does not have to use the same manufacturing process as the reference listed drug.
You may also be interested in...
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.